Semaglutide vs. Tirzepatide: Which GLP-1 Is Right for Your Weight Loss Goals?

Dr. Crystal Broussard, MD

Board Certified in Family Medicine  ·  Specialized Training in Obesity Medicine

Updated April 1, 2026

Semaglutide vs. Tirzepatide: Understanding Your GLP-1 Options for Weight Loss

If you have spent any time researching medical weight loss, you have probably encountered the names semaglutide and tirzepatide alongside their brand names: Ozempic, Wegovy, Mounjaro, and Zepbound. Many of my patients arrive at their first consultation already wondering whether semaglutide vs tirzepatide is the better choice. The honest answer is that both are highly effective FDA-approved medications for chronic weight management, yet they work through different mechanisms and produce different average outcomes in clinical research.

As a physician with Specialized Training in Obesity Medicine and nearly 20 years of clinical experience, I have guided many patients through this exact decision. The most current evidence comes from the SURMOUNT-5 trial, a 72-week head-to-head randomized study published in the New England Journal of Medicine, which found that tirzepatide produced approximately 20.2% mean weight loss compared to 13.7% with semaglutide in adults with obesity, with individual results varying considerably across both groups. New England Journal of Medicine 2025

In this article, I will walk you through how each medication works, what the clinical trials show, what to expect during treatment, and how I approach the medication selection process for each patient. My goal is to give you the information you need to have a meaningful conversation with your physician so you can feel confident in whatever path you choose.

Important Safety Information

Both semaglutide and tirzepatide carry a boxed warning for thyroid C-cell tumors observed in animal studies; the relevance to humans is currently unknown. FDA Wegovy Prescribing Information 2023 Both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. They are not recommended during pregnancy or breastfeeding. If you have a history of pancreatitis, diabetic retinopathy, severe gastrointestinal disease, or kidney disease, your physician will carefully review your history to discuss risks and benefits before recommending either medication. These are not over-the-counter products; they require physician evaluation, careful titration, and ongoing monitoring.

How Semaglutide and Tirzepatide Work: Mechanism of Action

To understand the difference between these two medications, it helps to understand how incretin hormones work. Incretins are naturally occurring gut peptides released after eating; they signal the brain to reduce appetite, prompt the pancreas to release insulin when blood sugar rises, and slow gastric emptying so you feel full longer.

Semaglutide is a GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1 (GLP-1), one of the primary incretin hormones. FDA Ozempic Prescribing Information 2022 It activates GLP-1 receptors in the brain to reduce appetite and cravings, in the pancreas to stimulate glucose-dependent insulin secretion, and in the stomach to slow gastric emptying. The result, for many patients, is a meaningful reduction in hunger and caloric intake that supports weight loss when combined with lifestyle changes. FDA Wegovy Prescribing Information 2023

Tirzepatide goes one step further. It is a dual GIP/GLP-1 receptor agonist, meaning it activates both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors. MedlinePlus 2024 GIP is a second incretin hormone that may enhance insulin sensitivity, support fat metabolism, and contribute to appetite regulation through mechanisms that differ somewhat from GLP-1 signaling. Research suggests this dual receptor activity may contribute to tirzepatide’s superior weight loss outcomes compared to semaglutide, though the precise role of GIP signaling in humans continues to be studied. New England Journal of Medicine 2025 Both medications are administered as once-weekly subcutaneous injections.

Weight Loss Outcomes: What the Clinical Trials Show

Tirzepatide Results: SURMOUNT Trials

The most compelling evidence for tirzepatide’s weight loss potential comes from the SURMOUNT program. In the SURMOUNT-1 trial, Jastreboff and colleagues enrolled 2,539 adults with obesity or overweight plus at least one weight-related condition (none had type 2 diabetes) and treated them with tirzepatide at 5 mg, 10 mg, or 15 mg weekly or placebo for 72 weeks. The results were substantial and dose-dependent: participants on the highest doses achieved an average weight reduction of approximately 20.9% compared to 3.1% with placebo, with 50 to 57% of participants on higher doses reaching at least 20% weight loss (versus 3% with placebo), and individual responses varied meaningfully across the study population. New England Journal of Medicine 2022 Gastrointestinal adverse events were the most common side effects and were generally mild to moderate.

The generalizability of these findings has been supported by additional research. The SURMOUNT-CN trial enrolled Chinese adults with obesity and found that tirzepatide at 10 mg and 15 mg produced weight reductions of 13.6% and 17.5% respectively versus 2.3% with placebo at 52 weeks, confirming consistent efficacy across diverse populations, with individual responses varying in that population as well. JAMA 2024

Beyond weight reduction, post hoc analysis of SURMOUNT-1 data indicates tirzepatide may significantly reduce the 10-year predicted risk of developing type 2 diabetes, with absolute risk reductions of 12.4 to 14.7% at 72 weeks versus 0.7% with placebo, an effect that was even more pronounced in participants who had prediabetes at baseline. Diabetes, Obesity and Metabolism 2023 For patients managing prediabetes alongside their weight goals, this metabolic dimension is worth discussing at your consultation.

Semaglutide Results: Weight Loss Efficacy

Semaglutide at the 2.4 mg weekly dose (Wegovy) has an established track record in clinical weight management. Evidence cited in the FDA prescribing information indicates meaningful average weight loss in adults with obesity over approximately 68 weeks, with significant improvements in cardiometabolic markers including blood pressure, blood sugar, and lipid levels. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) summarizes semaglutide (Wegovy) as one of the primary FDA-approved long-term weight loss medications, noting that its benefits are best realized in combination with diet and physical activity changes under physician supervision. NIDDK 2024

Semaglutide also has a longer track record in clinical use for weight management than tirzepatide, which received its FDA approval for obesity in late 2023. For some patients, that longer history of real-world use informs comfort with the medication as a starting point.

Head-to-Head Comparison: Tirzepatide vs. Semaglutide

The most direct evidence comes from the SURMOUNT-5 trial, which enrolled 751 adults with obesity without type 2 diabetes and compared tirzepatide (10 to 15 mg weekly) to semaglutide (1.7 to 2.4 mg weekly) over 72 weeks. Tirzepatide produced significantly greater mean weight loss of approximately 20.2% versus 13.7% with semaglutide, with larger reductions in waist circumference (18.4 cm versus 13.0 cm) and higher proportions of participants achieving weight loss thresholds of 10%, 15%, 20%, and 25%. Individual results varied across participants in both groups, and GI adverse events were common and similar in frequency between the two arms. It is worth noting that this trial used an open-label design, meaning participants and providers knew which medication was assigned. The results reflect outcomes at obesity-standard dosing for both agents (Aronne et al., New England Journal of Medicine, 2025).

Side Effects, Dosing, and What to Expect on Treatment

One of the first questions patients ask me is whether one medication has a better side effect profile. The honest answer is that semaglutide and tirzepatide share a similar side effect profile, and neither has demonstrated a clear tolerability advantage based on available evidence. Mayo Clinic 2023

The most common side effects for both medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects are typically mild to moderate in intensity, are most prominent during the dose escalation phase, and in most patients improve as the body adjusts to each new dose level. In my practice, most patients notice that GI symptoms ease within two to four weeks at each dose step.

Both medications use a gradual titration approach to minimize these effects. Semaglutide (Wegovy) is titrated from an initial 0.25 mg weekly up to a maintenance dose of 2.4 mg over approximately 16 to 20 weeks. FDA Wegovy Prescribing Information 2023 Tirzepatide (Zepbound) is titrated from a starting dose of 2.5 mg weekly up to maintenance doses of 10 mg or 15 mg over a similar period. MedlinePlus 2024 I adjust the titration schedule based on how each individual is tolerating the escalation steps. If GI effects are limiting quality of life at a given dose, holding at that level for additional weeks before advancing is a clinical option.

It is also worth knowing that some patients tolerate one medication better than the other. If side effects on one GLP-1 are persistent or limiting, switching to the other medication is an option worth discussing with your physician. And because both medications require ongoing use to maintain their effects, the most effective medication is the one you can sustain long term. Discontinuation of either medication typically results in gradual weight regain over time, which is why physician oversight and long-term planning are essential components of any GLP-1 program. Harvard Health Publishing 2024

Semaglutide and Tirzepatide for Weight Loss in Spring, TX and North Houston

I see patients from across the North Houston area who are navigating the same question: they have researched GLP-1 medications, they know they want physician supervision, and they want care that goes beyond a subscription app and a pharmacy shipment.

At Harmony Aesthetics Spa, physician-supervised GLP-1 therapy includes far more than a prescription. Every patient receives weekly InBody body composition monitoring, a clinical tool that measures fat mass and lean muscle mass separately rather than simply tracking scale weight. This matters because GLP-1 medications can, in some patients, contribute to lean muscle loss alongside fat reduction. Muscle loss slows metabolism, weakens balance, and can undermine long-term health even if the scale number looks favorable. I do not increase dosage when I observe meaningful muscle loss. That clinical decision reflects the kind of individualized physician oversight a physician-owned practice can provide. NIDDK 2024

Whether you are a working professional in The Woodlands or a parent juggling a busy household near Spring Creek Greenway, physician-supervised care means your treatment plan adjusts as your life does. I serve patients from Spring, TX and surrounding communities, including Tomball and Kingwood, at our Spring location (3466 Discovery Creek Blvd., Ste. 500, Spring, TX 77386).

When Is It Time to Talk to a Physician About GLP-1 Medications?

GLP-1 medications are not appropriate for every patient, but many people who could benefit from them have not yet started simply because they were unsure whether they qualified. Based on the FDA-approved criteria for these medications, here are the situations that may indicate you are a candidate. FDA 2023

If any of these situations resonates with you, a consultation is a worthwhile first step. I can review your health history, discuss whether semaglutide or tirzepatide may be a better starting point for your specific situation, and answer your questions without any pressure to commit.

What to Expect During Your GLP-1 Consultation and Treatment at Harmony Aesthetics Spa

Your first visit begins with a comprehensive health history review. I want to understand your previous weight loss attempts, your current metabolic health (including lab work if indicated), your current medications, and your personal goals. We discuss what success looks like for you, whether that is a specific weight target, improved energy, better blood sugar control, or returning comfortably to activities you have stepped back from.

From there, I determine which medication, semaglutide or tirzepatide, is the better starting point based on your individual profile. I walk you through the titration schedule: what to expect at each dose step, how to manage potential GI side effects in the early weeks, and when to reach out to our team if something does not feel right.

Every follow-up visit includes an InBody body composition scan. I track fat mass and lean muscle mass separately, not just total weight. If I observe early muscle loss, I address it through dosing decisions and nutritional guidance before it becomes a clinical concern. This monitoring approach is one of the most meaningful differences between a physician-owned medical spa and a prescription-and-go model. Patients in my practice receive their injections in-office at each visit. This ensures I see you regularly, that I can adjust your care as your body’s response evolves, and that we are building lasting metabolic health together, not just chasing a lower number on the scale.

Physician-Supervised vs. Online GLP-1 Programs: Key Differences

One Client’s Experience

In my practice, I know that reading about clinical trial percentages is one thing; hearing from a real patient about their experience is another. I appreciate when patients share how our team has helped them.

That kind of personalized guidance is at the heart of what we do. Results vary by individual, and outcomes depend on a range of factors including starting health status, lifestyle changes, and adherence to the treatment plan. What I can promise is that every patient receives individualized attention and a care plan built around their specific needs.

Making the Right Choice: Your Path Forward with GLP-1 Therapy

Both semaglutide and tirzepatide are highly effective FDA-approved options for medical weight loss, and evidence suggests tirzepatide produces greater average weight loss in head-to-head clinical comparisons. At the same time, the right medication is the one that works for your body, fits your health history, and that you can sustain over time under proper physician supervision. Numbers from clinical trials tell part of the story; your individual response tells the rest.

At Harmony Aesthetics Spa, I approach every weight loss consultation with the same philosophy I bring to all of my care: start with the patient’s full picture, not a protocol checklist. Results vary by individual, and outcomes depend on individual factors, including your metabolic health, adherence, and lifestyle changes alongside treatment. If you are ready to explore whether semaglutide or tirzepatide may support your weight loss goals, I would love to help you work through that decision.

Schedule a consultation with Dr. Crystal Broussard at Harmony Aesthetics Spa, serving patients throughout Spring, TX and the greater North Houston area. Call or text us at (346) 597-1202. We would love to answer your questions.

Frequently Asked Questions